Unique ID issued by UMIN | UMIN000044289 |
---|---|
Receipt number | R000050590 |
Scientific Title | The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer |
Date of disclosure of the study information | 2021/06/01 |
Last modified on | 2022/05/23 09:32:36 |
The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer
The prospective study of focal high-dose rate brachytherapy for low or intermediate risk prostate cancer
The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer
The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer
Japan |
Prostate cancer
Urology |
Malignancy
NO
The efficacy and safety for focal high-dose rate brachytherapy using Irisium for low or intermediate localized prostate cancer
Safety,Efficacy
Confirmatory
Pragmatic
Phase I,II
1.The efficacy for the value of serum PSA and MRI
2.The efficacy for pathological evaluation of re-biopsy of focal radiation region
The safety for focal high-dose rate brachytherapy using Irisium for clinically localized prostate cancer
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Focal high-dose rate brachytherapy for Prostate cancer using Irisium-192, 19Gy single fraction
20 | years-old | <= |
Not applicable |
Male
1.Prostate cancer diagnosed pathological examination
2.Only single region prostate cancer revealed same region, that suspcet of clinically significant cancer by mpMRI prior biopsy
3.Proatate cancer of Gleason score 3+3,3+4 or 4+3
4.Not ever accepte the therapy for prostate cancer
5.No metastasis region by radiological examination
6.PSA value less than 20ng/ml
7.Performance Status is 0, 1 or2
1.Prostate cancer region and size that unsuitable brachytherapy
2.multiple cancer region diagnosed by prostate biopsy
3.Medical history for radiation therapy of the pelvis
4.Unfit for regularly MRI examination for follow-up
5.Administration of glucocorticoid or 5-arufa reductase
6.Actively double cancer
20
1st name | Yoshiyuki |
Middle name | |
Last name | Miyaji |
Kawasaki Medical School Hospital
Department of Urology
701-0192
577, Matsushima, Kurashiki, Japan
086-462-1111
miyaji@med.kawasaki-m.ac.jp
1st name | Yoshiyuki |
Middle name | |
Last name | Miyaji |
Kawasaki Medical School Hospital
Department of Urology
701-0192
577, Matsushima, Kurashiki, Japan
086-462-1111
miyaji@med.kawasaki-m.ac.jp
Kawasaki Medical School Hospita, Department of Urology
Kawasaki Medical School Hospita, Department of Urology
Other
The ethics committee of Kawasaki Medical School and Hospital
577, Matsushima, Kurashiki, Japan
086-462-1111
kmsrec@med.kawasaki-m.ac.jp
NO
川崎医科大学附属病院(岡山県)
2021 | Year | 06 | Month | 01 | Day |
Unpublished
Suspended
2021 | Year | 05 | Month | 21 | Day |
2021 | Year | 08 | Month | 06 | Day |
2021 | Year | 08 | Month | 06 | Day |
2026 | Year | 03 | Month | 31 | Day |
2021 | Year | 05 | Month | 21 | Day |
2022 | Year | 05 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050590
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |